Success Story: EB-1A Approved in 20 Days with Premium Processing Service! We Assisted a VP to Secure Approval Swiftly
Client’s Testimonial:
“Thank you so much, this is tremendous news!!! I am really grateful for all the hard work, attention to detail, and pragmatic thinking. Thank you to everyone on the team!!!”
On December 9th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a VP in the Field of Biomedical Sciences (Approval Notice).
General Field: Biomedical Sciences
Position at the Time of Case Filing: VP
Country of Residence at the Time of Filing: United Kingdom
Approval Notice Date: December 9th, 2025
Processing Time: 20 days (Premium Processing Requested)
Case Summary:
We are pleased to celebrate another outstanding achievement secured through our firm’s expertise in preparing extraordinary-ability petitions. Our team recently obtained an EB-1A approval in just 20 days for the client, an exceptional researcher with a D.Phil. in biomedical sciences. The case was filed under direct premium processing, and remarkably, it was approved without any Request for Evidence, underscoring the strength and clarity of the evidence presented.
The client is an established expert in Biomedical Sciences, and within this broad domain, is recognized as a leading specialist. The client’s work is especially influential for advancing the understanding of antibody loop structures, a foundational component in developing next-generation targeted antibody therapeutics.
In the petition, we demonstrated the client’s extraordinary ability by highlighting a substantial scholarly record, including 8 peer-reviewed journal articles, 1 peer-reviewed conference article, and 1 preprint, with several contributions at the first-author level. Due to the exceptional applicability of these contributions, the client’s research has already accumulated 904 citations, reflecting the global impact and widespread reliance on their work in biomedical and computational sciences. In addition, the client has served as a peer reviewer at least 15 times for some of the most selective and influential international venues in artificial intelligence and computational research, further validating their authority in the field.
We also emphasized the client’s prior research support from prominent funding bodies known for their highly competitive selection standards. These included organizations such as the Engineering and Physical Sciences Research Council, UCB, Roche GmbH, and the Bill & Melinda Gates Foundation, each of which invests in scientific innovations that shape the future of human health.
To strengthen the petition, we included three expert recommendation letters from internationally respected researchers in computational biology and biomedical sciences. These letters confirmed the client’s pioneering contributions to machine-learning-driven drug discovery. As one expert stated:
“His research also benefits the wider U.S. by enhancing both short- and long-term health outcomes for affected patients, positioning the nation as a worldwide leader in healthcare and scientific innovation, especially for underserved subpopulations across minority groups.”
In presenting the case, our team emphasized how the client’s research advancements hold major significance for critical efforts in therapeutic development, personalized medicine, and computational approaches to biologic design. The petition clearly established that the client is among the small percentage of researchers at the very top of the field and that continued work in the United States will directly and substantially benefit the nation’s biomedical and healthcare innovation landscape.
With a meticulously prepared filing, compelling evidence, and strong strategic framing, the petition was approved swiftly, an outstanding result reflecting both the client’s extraordinary accomplishments and our firm’s commitment to delivering exceptional outcomes.